DexCom, Inc. (DXCM)
DXCM Stock Price Chart
Explore DexCom, Inc. interactive price chart. Choose custom timeframes to analyze DXCM price movements and trends.
DXCM Company Profile
Discover essential business fundamentals and corporate details for DexCom, Inc. (DXCM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
14 Apr 2005
Employees
10.20K
Website
https://www.dexcom.comCEO
Kevin Ronald Sayer
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DXCM Financial Timeline
Browse a chronological timeline of DexCom, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 11 Feb 2026
Upcoming earnings on 23 Oct 2025
EPS estimate is $0.57.
Earnings released on 30 Jul 2025
EPS came in at $0.48 surpassing the estimated $0.44 by +8.21%, while revenue for the quarter reached $1.16B , beating expectations by +2.89%.
Earnings released on 1 May 2025
EPS came in at $0.32 falling short of the estimated $0.33 by -2.20%, while revenue for the quarter reached $1.04B , beating expectations by +1.83%.
Earnings released on 13 Feb 2025
EPS came in at $0.45 falling short of the estimated $0.48 by -6.09%, while revenue for the quarter reached $1.11B , beating expectations by +0.39%.
Earnings released on 24 Oct 2024
EPS came in at $0.45 surpassing the estimated $0.44 by +2.27%, while revenue for the quarter reached $994.20M , beating expectations by +0.38%.
Earnings released on 25 Jul 2024
EPS came in at $0.43 surpassing the estimated $0.39 by +10.26%, while revenue for the quarter reached $1.00B , missing expectations by -3.17%.
Earnings released on 25 Apr 2024
EPS came in at $0.32 surpassing the estimated $0.27 by +18.52%, while revenue for the quarter reached $921.00M , beating expectations by +1.22%.
Earnings released on 8 Feb 2024
EPS came in at $0.50 surpassing the estimated $0.43 by +16.28%, while revenue for the quarter reached $1.03B , beating expectations by +2.01%.
Earnings released on 26 Oct 2023
EPS came in at $0.50 surpassing the estimated $0.34 by +47.06%, while revenue for the quarter reached $975.00M , beating expectations by +3.81%.
Earnings released on 27 Jul 2023
EPS came in at $0.34 surpassing the estimated $0.23 by +47.83%, while revenue for the quarter reached $871.30M , beating expectations by +3.53%.
Earnings released on 27 Apr 2023
EPS came in at $0.17 surpassing the estimated $0.15 by +13.33%, while revenue for the quarter reached $741.50M , beating expectations by +2.88%.
Earnings released on 9 Feb 2023
EPS came in at $0.34 surpassing the estimated $0.26 by +30.77%, while revenue for the quarter reached $815.20M , beating expectations by +0.63%.
Earnings released on 27 Oct 2022
EPS came in at $0.28 surpassing the estimated $0.24 by +16.67%, while revenue for the quarter reached $769.60M , beating expectations by +2.37%.
Earnings released on 28 Jul 2022
EPS came in at $0.17 matching the estimated $0.17, while revenue for the quarter reached $696.20M , missing expectations by -0.19%.
Stock split effective on 13 Jun 2022
Shares were split 4 : 1 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 10 Jun 2022
Shares were split 4 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 28 Apr 2022
EPS came in at $0.08 falling short of the estimated $0.13 by -38.46%, while revenue for the quarter reached $628.80M , beating expectations by +0.79%.
Earnings released on 10 Feb 2022
EPS came in at $0.17 falling short of the estimated $0.22 by -22.73%, while revenue for the quarter reached $698.20M , beating expectations by +0.10%.
Earnings released on 28 Oct 2021
EPS came in at $0.22 surpassing the estimated $0.16 by +37.50%, while revenue for the quarter reached $650.20M , beating expectations by +5.26%.
Earnings released on 29 Jul 2021
EPS came in at $0.19 surpassing the estimated $0.11 by +72.73%, while revenue for the quarter reached $595.10M , beating expectations by +15.82%.
Earnings released on 29 Apr 2021
EPS came in at $0.08 matching the estimated $0.08, while revenue for the quarter reached $505.00M , beating expectations by +4.22%.
Earnings released on 11 Feb 2021
EPS came in at $0.23 matching the estimated $0.23, while revenue for the quarter reached $568.90M , missing expectations by -1.08%.
Earnings released on 27 Oct 2020
EPS came in at $0.24 surpassing the estimated $0.16 by +50.00%, while revenue for the quarter reached $500.90M , beating expectations by +44.59%.
DXCM Stock Performance
Access detailed DXCM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.